Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurora SpineASAPF 38 Price-to-Tangible-Book is 4.26 as of Aug. 23, 2026, which is 16% below its 10-year median of 5.08. GuruFocus rates ASAPF with a GF Score™ of 38/100 and a GF Value™ of $0.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 700 Medical Devices & Instruments companies, Aurora Spine ranks worse than 67.14% on this metric.
The historical rank and industry rank for Aurora Spine's Price-to-Tangible-Book or its related term are showing as below:
ASAPF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.06 Med: 5.08 Max: 24.52
Current: 4.15
During the past 13 years, Aurora Spine's highest Price to Tangible Book Ratio was 24.52. The lowest was 1.06. And the median was 5.08.
ASAPF's Price-to-Tangible-Book is ranked worse than 67.14% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 2.715
vs ASAPF: 4.15
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Aurora Spine Price-to-Tangible-Book Related Terms
Aurora Spine Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Aurora Spine's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASAPF vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Aurora Spine's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Spine Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aurora Spine's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Aurora Spine's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Aurora Spine (ASAPF) has a Price-to-Tangible-Book of 4.26 as of Aug. 23, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Aurora Spine and its competitors. This is 16% below median its historical median of 5.08. Over the past decade, Aurora Spine's Price-to-Tangible-Book has ranged from 1.06 to 24.52. According to the industry distribution chart, Aurora Spine ranks #470 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 67.1%.
Is Aurora Spine's Price-to-Tangible-Book too high?
Aurora Spine's current Price-to-Tangible-Book of 4.26 is 16% below median its 10-year median of 5.08. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 24.52. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.72. Aurora Spine's value of 4.26 is 56.9% above this industry median. Based on the distribution chart, Aurora Spine ranks #470 out of 700 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Aurora Spine has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Spine's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aurora Spine ranks #470 out of 700 companies for Price-to-Tangible-Book. This places Aurora Spine in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.72. Aurora Spine's value of 4.26 is 56.9% above this benchmark. Historically, Aurora Spine's own Price-to-Tangible-Book has ranged from 1.06 to 24.52 over the past decade. While the company's 10-year median is 5.08 vs. the industry median of 2.72, Aurora Spine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.72, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Spine's current Price-to-Tangible-Book of 4.26 is 56.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Aurora Spine and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Spine's current Price-to-Tangible-Book is 4.26, which is 16% below median its own 10-year median of 5.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Spine stock overvalued right now?
Based on GuruFocus' analysis, Aurora Spine (ASAPF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.25, compared to a current price of $0.17 — trading 33.6% below its estimated fair value. The current Price-to-Tangible-Book is 4.26, which is 16% below median its 10-year median of 5.08 and 56.9% above the Medical Devices & Instruments industry median of 2.72. Aurora Spine's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Aurora Spine (ASAPF), the current Price-to-Tangible-Book is 4.26 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Spine (ASAPF) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Spine stock appears to be undervalued.
The current stock price of $0.17 is trading 33.6% below its estimated GF Value™ of $0.25.
GuruFocus considers Aurora Spine to be Possible Value Trap.
Key valuation signals for ASAPF:
Price-to-Tangible-Book: 4.26 (16% below median its 10-year median of 5.08)
GF Value™: $0.25 vs. price of $0.17 (33.6% below fair value)
Industry Position: 56.9% above the Medical Devices & Instruments median (#470 of 700)
No single metric tells the full story. See the ASAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Spine Corp is engaged in the development, manufacture, and sale of minimally invasive, interspinous fusion systems and devices. These 510K and patent protected medical devices improve patient outcomes in the area of spine and sacroiliac joint surgical procedures. The company is focused on bringing new solutions to the spinal implant market through a series of minimally invasive, regenerative spinal implant technologies.
38GF Score
Get the complete analysis for ASAPF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASAPF has been successfully added to your 
